Aggressive investors looking for some big-time alpha may like this microcap biotech. Mustang Bio Inc. (NASDAQ: MBIO) is a clinical-stage biopharmaceutical company focused on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor engineered T cell therapies for hematologic malignancies and for solid tumors.
The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment.
The towering $11 BTIG Research price target compares with a $10.40 consensus target and the almost $4 at which shares traded hands late in the week.
This is another microcap biotech for aggressive investors looking to the space for alpha potential. VistaGen Therapeutics Inc. (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company engaged in developing and commercializing various medicines with the potential to care for anxiety, depression and other disorders of the central nervous system (CNS).
The company’s pipeline includes the following:
- PH94B is a rapid-onset neuroactive nasal spray that is in preparation for Phase 3 development for the acute treatment of anxiety in adults with social anxiety disorder. It also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, panic and others.
- TPH10 is a rapid-onset neuroactive nasal spray that is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD).
- AV-101 is an oral N-methyl-D-aspartate receptor antagonist that is in development in combination with probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain and suicidal ideation.
The company has contract research and development agreement with Cato Research, license and option agreements with Pherin Pharmaceuticals, a license and collaboration agreement with EverInsight Therapeutics and a license and sublicense agreement with BlueRock Therapeutics.
Baird has set a $9 price target. The lower consensus target is $6.50. Shares have traded mostly between $2 and $3 apiece since early in the year.
After a recent IPO, this stock has solid upside potential. Waterdrop Inc. (NYSE: WDH) is the second-largest online insurance distribution platform in China. It distributes both short-term and long-term insurance products for insurers via its insurance marketplace. Waterdrop also owns Waterdrop Medical Crowdfunding, the largest online medical crowdfunding platform in China.
The company will focus until 2025 on growing its online insurance business in China, and it would like to expand further into health care businesses there in a decade. The company said in its IPO filing that its revenue hit ¥3 billion ($464.43 million), an increase of over 100% year on year.
Morgan Stanley analysts have an $11.80 price target. There is no consensus target yet. The stock has traded hands above $8 a share since the beginning of the month.
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with absolutely no track record or liquidity, and major Wall Street firms have research coverage.
Sponsored: Tips for Investing
A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.
Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.